Paraneoplastic Pemphigus (Paraneoplastic Autoimmune Multiorgan Syndrome) Expanded Antibody Panel by IIF With ELISA

Also known as: PNP PLUS

Clinical Use

Use

The Paraneoplastic Pemphigus (Paraneoplastic Autoimmune Multiorgan Syndrome) Expanded Antibody Panel is used to aid in the diagnosis and monitoring of paraneoplastic pemphigus. This condition is a rare paraneoplastic disease associated with lymphoproliferative disorders or malignancies and exhibits clinical features of severe pemphigus with a high mortality rate. The test detects IgG antibodies to multiple epithelial antigens, including envoplakin, which correlate with the extent of mucocutaneous disease in patients with this syndrome. Monitoring the antibody levels can assist in assessing disease expression and activity, particularly in response to therapy.

Special Instructions

Not provided.

Limitations

The test is performed in a CLIA-certified laboratory and not FDA cleared or approved, as FDA clearance is not required for clinical purposes. The sensitivity of indirect immunofluorescence can vary, and while ELISA is generally more sensitive for detecting antibodies, it may not detect low levels. Negative results do not rule out paraneoplastic/malignancy-associated disease, and clinical correlation is essential with histopathological examination and other epithelial antibodies in serum. Various tests might have differing sensitivities and specificities for detecting antibodies associated with PNP/PAMS.

Test Details

New York Approved